The FDA recently released a new regulation around Decentralized Manufacturing and Compliance in Modern Pharmaceutical Manufacturing, focused on 21 CFR 207 Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments (2026). The regulation focuses on requirements around designing a decentralized manufacturing platform using a hub-and-spoke model. In … [Read more…]